CRISPR Therapeutics AG (NASDAQ: CRSP)’s stock price has plunge by -4.03relation to previous closing price of 55.53. Nevertheless, the company has seen a -0.97% plunge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-08 that CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to loss of $0.67 per share a year ago.
Is It Worth Investing in CRISPR Therapeutics AG (NASDAQ: CRSP) Right Now?
Moreover, the 36-month beta value for CRSP is 1.79. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for CRSP is 81.24M and currently, short sellers hold a 18.15% of that float. On May 09, 2024, CRSP’s average trading volume was 1.72M shares.
CRSP’s Market Performance
The stock of CRISPR Therapeutics AG (CRSP) has seen a -0.97% decrease in the past week, with a -18.25% drop in the past month, and a -18.91% fall in the past quarter. The volatility ratio for the week is 3.49%, and the volatility levels for the past 30 days are at 4.04% for CRSP. The simple moving average for the last 20 days is -5.62% for CRSP stock, with a simple moving average of -10.37% for the last 200 days.
Analysts’ Opinion of CRSP
TD Cowen, on the other hand, stated in their research note that they expect to see CRSP reach a price target of $30. The rating they have provided for CRSP stocks is “Underperform” according to the report published on December 11th, 2023.
CRSP Trading at -20.36% from the 50-Day Moving Average
After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.50% of loss for the given period.
Volatility was left at 4.04%, however, over the last 30 days, the volatility rate increased by 3.49%, as shares sank -13.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.20% lower at present.
During the last 5 trading sessions, CRSP fell by -0.97%, which changed the moving average for the period of 200-days by -6.06% in comparison to the 20-day moving average, which settled at $56.04. In addition, CRISPR Therapeutics AG saw -14.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRSP starting from Kulkarni Samarth, who sale 19,582 shares at the price of $59.91 back on Apr 15 ’24. After this action, Kulkarni Samarth now owns 208,122 shares of CRISPR Therapeutics AG, valued at $1,173,232 using the latest closing price.
Kulkarni Samarth, the Chief Executive Officer of CRISPR Therapeutics AG, sale 20,000 shares at $72.48 during a trade that took place back on Mar 15 ’24, which means that Kulkarni Samarth is holding 208,122 shares at $1,449,628 based on the most recent closing price.
Stock Fundamentals for CRSP
Current profitability levels for the company are sitting at:
- -0.6 for the present operating margin
- 0.65 for the gross margin
The net margin for CRISPR Therapeutics AG stands at -0.42. The total capital return value is set at -0.1. Equity return is now at value -8.17, with -6.87 for asset returns.
Based on CRISPR Therapeutics AG (CRSP), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -1.09. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is 12.51.
Currently, EBITDA for the company is -202.7 million with net debt to EBITDA at 0.71. When we switch over and look at the enterprise to sales, we see a ratio of 11.82. The receivables turnover for the company is 1.85for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.54.
Conclusion
To wrap up, the performance of CRISPR Therapeutics AG (CRSP) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
